RxDoctor Payments Data

Purnima Thakran

Neurology · Apple Valley, CANPI 1184706616

Payments from drug & device makers

$28,275in general payments, 2019–2025

Across 395 payments — averaging $71.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$15K
  • SK Life Science, Inc.$7K
  • Livanova USA, Inc.$1K
  • AbbVie$773
  • Novartis$715
  • UCB, Inc.$675
  • plus $4K from 30 others

What the payments were for

  • Consulting fees$4,05014%
  • Speaking & faculty fees$11,36040%
  • Travel & lodging$5,13618%
  • Food & beverage$7,53027%
  • Education$2001%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,275 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$6,217
Medicare patients
29
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AptiomEslicarbazepine Acetate39$98,469
BriviactBrivaracetam26$58,532
Trokendi XrTopiramate17$26,303
QuliptaAtogepant21$24,793
UbrelvyUbrogepant22$21,894
XcopriCenobamate11$18,692
FycompaPerampanel13$14,654
Topiramate ErTopiramate11$13,922
Rufinamide12$6,247
Amitriptyline Hcl146$3,648
Celecoxib24$2,958
Etodolac42$2,505
Levetiracetam58$2,350
Tizanidine Hcl30$2,164
Rosuvastatin Calcium62$1,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$14,541$98,46939 claims
UCB, Inc.Briviact$675$58,53226 claims
AbbVieQulipta, Ubrelvy$773$46,68743 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$642$26,30317 claims
SK Life Science, Inc.Xcopri$6,625$18,69211 claims
Eisai Inc.Fycompa$222$14,65413 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$27$71647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →